Radioisotopes in different physical and chemical forms other than being used as radiation sources for therapy have tremendous applications as tracers for diagnosis in nuclear medicine as well as in drug discovery and drug development. The Department of Radiopharmacy, in cooperation with Nuclear Science and Technology Research Institute of Iran Atomic Energy Organization, has established the Ph.D. program in radiopharmacy to provide graduate education and research for development and the safe use of radiopharmaceuticals. The graduates of this program have had great contribution to self-sufficiency of the country for most radiopharmaceuticals, fulfilled national universities and research institutions, demands to scholars and expertise in this field, and results of their investigations have been granted as patents and published in numerous highly cited articles. The aim of this Department is to enhance development of the graduate students as the next generation of scholars in this field through promotion of the quality of both education and research.
With increasing use of radiopharmaceuticals in diagnosis, therapy and research and in order to fulfill national demands for expertise in this field, Department of Medicinal Chemistry, with contributions of Iran Atomic Energy Organization, established the Ph.D. program in radiopharmacy in 1995. The program was revised in 2002, and since 2009, is offered by an independent Department called Radiopharmacy. Most graduates of this program have been working in national universities and Nuclear Science and Technology Research Institute of Iran Atomic Energy Organization and are well known nationally and internationally for development of radiopharmaceuticals and research achievements.
Mission
The main mission of the Department of Radiopharmacy is to offer internationally recognized and high quality education and research that fulfills the national demands for future scholars and expertise in this field. The program affords individuals the scientific knowledge and skills in design, preparation, formulation and quality control of gamma and positron emitting radiopharmaceuticals for use in research and future clinical applications in nuclear medicine. The Department is actively engaged in the development of radiolabelled monoclonal antibodies, radiosensitizing agents, and contrast media for MRI, nanoradiopharmacy, and molecular imaging.
Vision
We aim to be recognized nationally and internationally for education and research in development and safe use of novel radiopharmaceuticals.
All interested applicants are welcome to apply to TUMS by completing and submitting TUMS online application form in which they need to specify their school, level, and major of interest.